COPPELL, Texas--(BUSINESS WIRE)--Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced it has assembled a group of top-tier, independent scientists to lead its Global Scientific Advisory Board that will support the company’s continued commitment to providing groundbreaking, science-backed nutritional supplements to its worldwide customer base.
“The members of Mannatech’s Global Scientific Advisory Board are committed to science and the truth that their research and findings bring,” said Mannatech’s CEO and President, Alfredo “Al” Bala. “Mannatech has built its worldwide business on science-backed product technology, and this group will help us continue that tradition and take us into new, transformational areas of health and wellness, while ensuring we stay on the path of scientific proof and validation.”
This Global Scientific Advisory Board is part of CEO and President Al Bala’s vision for ensuring that Mannatech delivers innovative nutritional technology and products that are supported by clinical trials and scientific validation. The board safeguards that Mannatech products are what they say they are and can provide real results by improving the overall wellness of customers*.
Mannatech’s Global Scientific Advisory Board is specifically charged to review each new and existing product to ensure ingredients and formulations are kept to a high standard and are in-line with the latest research. The board will also be called upon to make suggestions for new products. Additionally, board members will provide education and training to Associates and customers on health and wellness topics.
The Mannatech Global Scientific Advisory Board consists of third-party, independent scientists from around the world. The board members include:
- Azita Alavi, BSc(Hons), M.Phil. Ph.D.
- Richard J. Bloomer, Ph.D.,
- Stephen Boyd, MD, Ph.D.
- Charl Marais, DEmed
- Francesco Marotta, MD Ph.D.
- Erika Nelson, Ph.D.
- Chandan Prasad, MS, Ph.D.
- Emma Roca, MS
- William Sanchez, MD
Mannatech’s Senior Global Wellness Director, Dr. Steve Nugent, will serve as Chairman of the Global Scientific Advisory Board and Dr. Rolando Maddela, Mannatech’s Director of Clinical Research and Scientific Affairs, will serve as the Executive Secretary. Mr. Tait Switzer, Vice President of Research and Development, will also support the scientific advisory board members.
“Innovative technology supported by a sound scientific foundation is at the heart of Mannatech’s products and ultimately, its success,” said Dr. Nugent. “Mannatech’s Global Scientific Advisory Board will ensure that we remain on the cutting edge of nutritional technology. This is an amazing group of minds that are focused on making the world a better place. By working together, we can find more ways to improve the health and wellness of as many people as possible. These individuals will retain their independence, but their position on the advisory board will give them a unique vantage point to the health and wellness community around the globe, as well as an opportunity to share their point of view with an audience that is in need of their service.”
Mannatech’s commitment to science includes clinical studies on its product technology and a global patent program. Since its founding, Mannatech has invested more than $50 million in research and development that includes a clinical testing program for a number of its products that helps supports core product claims and ensures that the company delivers what is promised. Mannatech’s core technology has been included in 17 human clinical trials that have been published, 12 of which were double-blind, placebo-controlled studies — the gold standard for product validation.
Mannatech’s Global Science Advisory Board was introduced to thousands of its leaders and independent sales Associates earlier this month at MannaFest 2016. The board will meet and provide input to Mannatech on a regular basis.
To begin transforming your life or the lives of those around you, please visit Mannatech.com.
*This statement has not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Mannatech, Incorporated, offers a profound wellness experience through a financially rewarding opportunity that makes a difference in the lives of people across the world. Through its innovative glyconutrition products, Mannatech transforms lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in more than 25 countries, Mannatech is committed to transforming lives. For more information, visit Mannatech.com.
Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.